Bicycle Therapeutics Exceeds Revenue Expectations
Cambridge-based pharma company Bicycle Therapeutics saw its share price rise on Nasdaq after reporting Q3 revenues of $11.73 million, surpassing the consensus estimate of $8 million.
The company is also making progress with its new cancer drug, zelenectide pevedotin, which targets Nectin-4 associated cancers, including urothelial, breast, lung, bladder, gastric, pancreatic, ovarian, and head & neck cancers.
A source noted that Bicycle is "excited about regulatory feedback across various geographies" regarding the potential advancement of its pipeline.
- Dose selection from the Phase 2/3 Duravelo-2 trial is expected in Q1 2026.
- An update on the potential approval pathway is also anticipated in Q1 2026.
Bicycle seeks feedback from multiple regulatory agencies as it moves forward with its cancer drug development.
Author's summary: Bicycle Therapeutics beats revenue expectations with $11.73 million in Q3 2025.
More News
- Letter: State lawmakers must be careful with False Claims Act
- Quick start, steady goaltending propel Sharks to first home win of season
- ‘Avatar: The Last Airbender,’ comes to life through on-stage orchestra
- Sharks Turn Back Clock, Rock Devils 5-2
- Pascendi and the Pope Who Didn't 'Trust the Science'
- OpenAI’s ChatGPT Atlas: A Bold Browser That Could Shake Up Google
- When An Infant Spoke and the Apostles Stayed Silent: A Lesson for the Modern Age
- Senior Woolworths executive sues retailer, Banducci for discrimination
- Bravo Network Cashes in on Paid Apostasy and Anti‑LDS Bigotry